The first launch is a down payment: this earnings season rewards the label that funds the next one
Kura, Autolus, ADC Therapeutics and others are using first-product revenue to underwrite a second act. The risk is trying to do both at once.
The pattern behind the quarter
Read the third-quarter reports side by side and the headline numbers matter less than what sits next to them. Kura Oncology reported KOMZIFTI net product revenue of $13.9 million, up 53% sequentially, with total prescriptions up 65%. In the same release it announced eight ASH abstracts, FDA alignment on a roughly 40-patient registrational study for darlifarnib, and combination studies slated for 2027. Autolus posted AUCATZYL revenue of $41.2 million, up 95% year over year, and has trials enrolling in lupus nephritis, pediatric ALL and progressive multiple sclerosis. ADC Therapeutics reported $21 million of net product revenue and pointed to ASH abstracts across multiple B-cell malignancies for ZYNLONTA.
This is not coincidence. The first approved indication is no longer the destination. It is the platform, and the companies doing best this season are treating it that way.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Reimbursement, not approval, is the commercial gate, and leaders should plan accordingly
This month's payer decisions from CMS, China's NRDL and Medicare show that price and access are set by policy calendars. Companies that treat them as afterthoughts will pay for it.
Show your working: launch revenue is the lagging indicator, and this season proves it
Headline growth rates from small launches are easy to produce and hard to compare. The results that persuade pair revenue with evidence of demand and a plan the economics can fund.
Gross margin is the number that turns a launch into a business
Revenue growth was easy to find in this earnings season. The companies that pair it with unit economics, as Delcath and Autolus have begun to, are the ones that will set their own terms.